Loading company
Moleculin Biotech, Inc. (MBRX) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $0 | $0 | 10-K 2026-03-18 · proof | |
| Operating income | -$25.1 million | -$26.6 million | 10-K 2026-03-18 · proof | |
| Net income | -$33.6 million | -$26 million | 10-K 2026-03-18 · proof | |
| Cash from operating activities | -$22.7 million | -$23.9 million | 10-K 2026-03-18 · proof | |
| Free cash flow | -$22.7 million | -$23.9 million | 10-K 2026-03-18 · proof | |
| Total assets | $22.1 million | $16.9 million | +30.7% | 10-K 2026-03-18 · proof |
| Total liabilities | $7.1 million | $5.7 million | +24.5% | 10-K 2026-03-18 · proof |
| Cash and cash equivalents | $8.9 million | $4.3 million | +107.5% | 10-K 2026-03-18 · proof |
- What was Moleculin Biotech, Inc. (MBRX)'s revenue in fiscal 2025?
- Moleculin Biotech, Inc. (MBRX) reported revenue of $0 for fiscal 2025 (the year ended Dec 31, 2025), against $0 the year before. Source: the 10-K filed with the SEC on Mar 18, 2026. SEC
- What was Moleculin Biotech, Inc. (MBRX)'s operating income in fiscal 2025?
- Moleculin Biotech, Inc. (MBRX) reported operating income of -$25.1 million for fiscal 2025 (the year ended Dec 31, 2025), against -$26.6 million the year before. Source: the 10-K filed with the SEC on Mar 18, 2026. SEC
- What was Moleculin Biotech, Inc. (MBRX)'s net income in fiscal 2025?
- Moleculin Biotech, Inc. (MBRX) reported net income of -$33.6 million for fiscal 2025 (the year ended Dec 31, 2025), against -$26 million the year before. Source: the 10-K filed with the SEC on Mar 18, 2026. SEC
- What was Moleculin Biotech, Inc. (MBRX)'s cash from operating activities in fiscal 2025?
- Moleculin Biotech, Inc. (MBRX) reported cash from operating activities of -$22.7 million for fiscal 2025 (the year ended Dec 31, 2025), against -$23.9 million the year before. Source: the 10-K filed with the SEC on Mar 18, 2026. SEC
- What was Moleculin Biotech, Inc. (MBRX)'s free cash flow in fiscal 2025?
- Moleculin Biotech, Inc. (MBRX) reported free cash flow of -$22.7 million for fiscal 2025 (the year ended Dec 31, 2025), against -$23.9 million the year before. Source: the 10-K filed with the SEC on Mar 18, 2026. SEC
- What are Moleculin Biotech, Inc. (MBRX)'s total assets?
- As of Dec 31, 2025, Moleculin Biotech, Inc. (MBRX) reported total assets of $22.1 million, against $16.9 million a year earlier (+30.7%). Source: the 10-K filed with the SEC on Mar 18, 2026. SEC
- What are Moleculin Biotech, Inc. (MBRX)'s total liabilities?
- As of Dec 31, 2025, Moleculin Biotech, Inc. (MBRX) reported total liabilities of $7.1 million, against $5.7 million a year earlier (+24.5%). Source: the 10-K filed with the SEC on Mar 18, 2026. SEC
- What are Moleculin Biotech, Inc. (MBRX)'s cash and cash equivalents?
- As of Dec 31, 2025, Moleculin Biotech, Inc. (MBRX) reported cash and cash equivalents of $8.9 million, against $4.3 million a year earlier (+107.5%). Source: the 10-K filed with the SEC on Mar 18, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:MBRX&period_type=annual&limit=5"Information only, not investment advice.